Home Cart Sign in  
Chemical Structure| 220991-20-8 Chemical Structure| 220991-20-8

Structure of Lumiracoxib
CAS No.: 220991-20-8

Chemical Structure| 220991-20-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lumiracoxib is a COX2 selective inhibitor and a non-steroidal anti-inflammatory drug (NSAID), which inhibits COX2 with IC50 and Ki values of 0.14 μM and 0.06 μM and inhibits COX1 with Ki of 3 μM.

Synonyms: COX-189

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lumiracoxib

CAS No. :220991-20-8
Formula : C15H13ClFNO2
M.W : 293.72
SMILES Code : O=C(O)CC1=CC(C)=CC=C1NC2=C(F)C=CC=C2Cl
Synonyms :
COX-189
InChI Key :KHPKQFYUPIUARC-UHFFFAOYSA-N
Pubchem ID :151166

Safety of Lumiracoxib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • COX-2

    COX-2, Ki:60 nM

  • COX-1

    COX-1, Ki:3 μM

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Thermal hyperalgesia model Oral 0, 1, 3, 10, 30 mg/kg Single dose, lasting 10 hours (experiment I) or 24 hours (experiment II) To evaluate the analgesic effects of Lumiracoxib and establish a pharmacokinetic/pharmacodynamic model. Results showed that Lumiracoxib significantly reversed carrageenan-induced hyperalgesia at doses of 10 and 30 mg/kg. PMC2823363
Mice Chronic oral corticosterone-induced anxiety-like behavior model Intraperitoneal injection 5 mg/kg Acute: single dose; Repeated: once daily for 13 days To investigate the effects of Lumiracoxib on chronic corticosterone-induced anxiety-like behavior and amygdala glutamatergic signaling. Results showed that both acute and repeated administration of Lumiracoxib reversed chronic corticosterone-induced anxiety-like behavior and normalized spontaneous excitatory glutamatergic currents in anterior basolateral amygdala neurons. PMC6710559
Rats 5-day short-term tolerability model Oral 2 mg/kg Once daily for 4 consecutive days Lumiracoxib substantially prevented roflumilast-mediated loss, spleen weight loss, leukocytosis, blood neutrophilia, and induction of serum CINC-1. PMC3031062

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00170898 Musculoskeletal Pain PHASE4 COMPLETED - For site information contact, ... More >>Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom Less <<
NCT00348491 Pain PHASE4 COMPLETED - Dental Research Clinic, Austin... More >>, Texas, 78703, United States Less <<
NCT00419796 Osteoarthritis With Controlled... More >> Hypertension Less << PHASE4 COMPLETED 2025-09-07 Novartis, East Hanover, New Je... More >>rsey, 07936-1080, United States Less <<
NCT00170872 Osteoarthritis|Rheumatoid Arth... More >>ritis Less << PHASE3 COMPLETED - -
NCT00267215 Osteoarthritis PHASE3 COMPLETED - Novartis, Nuernberg, Germany
NCT00350155 Healthy Volunteers PHASE4 COMPLETED - Wiesbaden, Germany|Nottingham,... More >> United Kingdom Less <<
NCT00170781 Acute Gouty Arthritis PHASE4 COMPLETED - Novartis, Nuernberg, Germany|F... More >>or Site Information, contact Novartis Pharma AG, Basel, CH, 4002, Switzerland Less <<
NCT00333567 Pain PHASE4 COMPLETED - Novartis, Nuernberg, Germany
NCT00145301 Osteoarthritis PHASE3 COMPLETED - Novartis, Nuernberg, Germany
NCT00475800 Osteoarthritis PHASE3 COMPLETED - Tucson, Arizona, 85723, United... More >> States|Brooklyn Park, Minnesota, 55430, United States|Albuquerque, New Mexico, 87109, United States|Sioux Falls, South Dakota, 57105, United States|San Antonio, Texas, 78232, United States|Novartis Investigative Site, Brampton, Ontario, Canada Less <<
NCT00366938 Osteoarthritis, Knee PHASE3 COMPLETED - Novartis Pharmaceuticals Corpo... More >>ration, E. Hanover, New Jersey, 07936, United States Less <<
NCT00367315 Knee Osteoarthritis PHASE3 COMPLETED - Novartis, Nuernberg, Germany|N... More >>ovartis, Basel, Switzerland Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.40mL

0.68mL

0.34mL

17.02mL

3.40mL

1.70mL

34.05mL

6.81mL

3.40mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories